MD Anderson Center
Welcome,         Profile    Billing    Logout  
 33 Trials 
55 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tsimberidou, Apostolia
NCT03592264: A Phase I/II Study of OBI-3424 in Subjects With Advanced Solid Tumors

Terminated
1/2
68
US
OBI-3424
OBI Pharma, Inc
Solid Tumor, Pancreatic Adenocarcinoma
02/24
03/24
NCT04084366: Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors

Terminated
1/2
44
US
OBI-999
OBI Pharma, Inc
Locally Advanced Solid Tumor
10/23
10/23
NCT03195699: Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Active, not recruiting
1
60
US
TTI-101
Tvardi Therapeutics, Incorporated, M.D. Anderson Cancer Center
Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Melanoma, Advanced Cancer
12/24
12/24
C-800-01, NCT03860272: Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Recruiting
1
550
Europe, US
Botensilimab, AGEN1181, Anti-CTLA-4, Balstilimab, AGEN2034, Anti-PD-1
Agenus Inc.
Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer
 
 
ORB, NCT05947474: -011 In Patients With Advanced Solid Tumors

Recruiting
1
36
US
ORB-011
Orionis Biosciences Inc
Advanced Solid Cancer
03/25
06/25
NCT05092373: Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Recruiting
1
43
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL-184, XL184, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Tumor Treating Fields Therapy, Alternating Electric Field Therapy, TTF, TTFields
M.D. Anderson Cancer Center
Advanced Breast Carcinoma, Advanced Endometrial Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Malignant Abdominal Neoplasm, Advanced Malignant Female Reproductive System Neoplasm, Advanced Malignant Thoracic Neoplasm, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Renal Cell Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Malignant Abdominal Neoplasm, Malignant Solid Neoplasm, Metastatic Breast Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Malignant Abdominal Neoplasm, Metastatic Malignant Female Reproductive System Neoplasm, Metastatic Malignant Thoracic Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Metastatic Renal Cell Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
09/26
09/26
IMPACT II, NCT02152254: Initiative for Molecular Profiling and Advanced Cancer Therapy

Active, not recruiting
N/A
1362
US
Targeted Therapy Based on Molecular Profiling, Standard-of-Care Therapy
M.D. Anderson Cancer Center, Tempus AI
Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
12/24
12/24
Kupfer, Sonia
NCT05680012: Tissue Destruction and Healing in Celiac Disease

Recruiting
N/A
220
US
Gluten containing snack bar
University of Chicago, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Mayo Clinic, California Institute of Technology
Celiac Disease
06/27
06/27
DEMETRA, NCT05732623: Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer

Recruiting
N/A
2300
Europe, US
Semi Quantitative Food Frequency Questionnaire (SQFFQ)
San Raffaele University, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy, Ospedale Civile Guglielmo da Saliceto, Piacenza, Italy, Centro di Riferimento Oncologico di Aviano, Aviano, Italy, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Bari, Italy, Gastroenterology Unit, University Hospital of Padova, Padova, Italy, Clinical Gastroenterology Unit, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy, IRCCS Arcispedale S. Maria Nuova - Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy, Azienda Ospedaliera San Gerardo di Monza, Monza, Italy, Azienda ULSS5 Polesana, Rovigo, Italy, Istituto Tumori Regina Elena - IRCCS IFO, Roma, Italy, University Hospital of Padova, Padova, Italy, IRCCS De Bellis, Castellana Grotte, Italy, University Hospital HELIOS Klinikum Wuppertal, Center for Hereditary Tumors, University of Witten-Herdecke, Wuppertal, Germany, Hospital of the University of Munich (LMU), Campus Großhadern, Munich, Germany, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain, Helsinki University Hospital, Helsinki, Finland, Oslo University Hospital (OUS), Institute for Cancer Genetics and Informatics Norwegian Radium Hospital, Oslo, Norway, Department of Medicine University of Chicago Medicine, Illinois, USA, University of Colorado Hospital, CO, USA, University of Michigan Ann Arbor, Michigan, USA, Columbia University Irving Medical Center, New York, NY, The James Comprehensive Cancer Center, Columbus, OH, USA, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA, Cleveland Clinic Main Campus, Cleveland, OH, USA, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia
Colorectal Cancer, Early Onset Colorectal Cancer, Diet Habit, Risk Reduction
01/30
01/35
PRECEDE, NCT04970056: Pancreatic Cancer Early Detection Consortium

Recruiting
N/A
8000
Europe, Canada, US, RoW
Arbor Research Collaborative for Health
Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
12/30
12/30
Yap, Timothy A
NCT05327010: Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

Recruiting
2
88
US
BET Bromodomain Inhibitor ZEN-3694, BETi ZEN-3694, ZEN 3694, ZEN-3694, ZEN003694, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Diagnostic Imaging, Medical Imaging, Talazoparib, BMN 673, BMN-673
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
08/25
08/25
NCT05700721: Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Recruiting
2
120
US
Niraparib, MK-4827, Dostarlimab
M.D. Anderson Cancer Center
Brain Metastases
08/25
08/27
NCT05082025: Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

Active, not recruiting
2
7
US
Copanlisib, fulvestrant
M.D. Anderson Cancer Center, Bayer
Endometrial Cancer, Ovarian Cancer
10/26
10/26
NCT04020185: Safety and Efficacy Study of IMSA101 in Refractory Malignancies

Completed
1/2
40
US
IMSA101, Immune checkpoint inhibitor (ICI), Immuno-oncology (IO) therapy
ImmuneSensor Therapeutics Inc.
Solid Tumor, Adult
09/23
09/23
NCT04317105: Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

Active, not recruiting
1/2
102
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Copanlisib Hydrochloride, 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2), Aliqopa, BAY 80-6946 Dihydrochloride, BAY-80-6946 Dihydrochloride, Copanlisib Dihydrochloride, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
12/24
12/24
TRESR, NCT04497116 / 2020-000301-87: Study of RP-3500, Camonsertib, in Advanced Solid Tumors

Recruiting
1/2
285
Europe, Canada, US
RP-3500 (camonsertib), Talazoparib, Gemcitabine Injection
Repare Therapeutics, Roche Pharma AG
Advanced Solid Tumor
07/25
12/25
NCT03997968: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Active, not recruiting
1/2
170
US
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Cyteir Therapeutics, Inc.
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
07/24
12/24
NCT04266912: Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

Active, not recruiting
1/2
25
US
Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Berzosertib, 2-Pyrazinamine, 3-(3-(4-((Methylamino)methyl)phenyl)-5-isoxazolyl)-5-(4-((1-methylethyl)sulfonyl)phenyl)-, M 6620, M6620, VX 970, VX-970, VX970
M.D. Anderson Cancer Center
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
09/24
09/24
NCT06077877: A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Recruiting
1/2
135
Canada, US
GSK4524101, Niraparib
GlaxoSmithKline
Neoplasms
12/27
11/29
NCT06065059: Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Terminated
1/2
7
US
TNG348, Olaparib, Lynparza
Tango Therapeutics, Inc.
Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer, BRCA1 Mutation, BRCA-Mutated Ovarian Carcinoma, BRCA-Associated Breast Carcinoma, HRD Positive Advanced Ovarian Cancer
05/24
05/24
PETRA, NCT04644068: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Calendar Jan 2024 - Dec 2024: Data from PETRA trial for advanced solid malignancies
Recruiting
1/2
804
Europe, Canada, Japan, US, RoW
AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd, Camizestrant
AstraZeneca
Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5
12/26
12/26
NCT04729725: SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL

Terminated
1b
3
US
Anti-TGF-beta Monoclonal Antibody SAR-439459, Anti-TGFb SAR-439459, Anti-transforming Growth Factor-beta mAb SAR439459, SAR 439459, SAR-439459, SAR439459, Cemiplimab, Cemiplimab RWLC, Cemiplimab-rwlc, Libtayo, REGN2810
M.D. Anderson Cancer Center
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
12/22
12/22
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Recruiting
1
475
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
GlaxoSmithKline
Neoplasms
08/25
02/27
NCT04197713: Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

Checkmark Results from combination of Olaparib followed by adavosertib for advanced solid tumors with selected mutations and PARP resistance
Nov 2022 - Nov 2022: Results from combination of Olaparib followed by adavosertib for advanced solid tumors with selected mutations and PARP resistance
Active, not recruiting
1
16
US
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
02/23
09/24
NCT04053673: Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors

Recruiting
1
130
Europe, US
RBN-2397
Ribon Therapeutics, Inc.
Solid Tumor, Adult
06/23
07/23
DRAGON, NCT04291079: SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
112
US, RoW
SRK-181, anti-PD-(L)1 antibody therapy
Scholar Rock, Inc.
Cancer
12/24
12/24
NCT06130254: Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Recruiting
1
52
US
Adagrasib, MRTX849, Olaparib, Lynparza™
M.D. Anderson Cancer Center, Mirati Therapeutics Inc.
Advanced Solid Tumor, Non-small Cell Lung Cancers
08/28
08/30
BGB-A317-15025-101, NCT04649385: BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

Recruiting
1
330
US, RoW
BGB-15025, Tislelizumab, BGB-A317
BeiGene
Advanced Solid Tumor
03/25
03/25
DDRiver Solid Tumours 301, NCT04170153: Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Active, not recruiting
1
204
Europe, Japan, US, RoW
M1774, Tuvusertib, Niraparib
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Metastatic or Locally Advanced Unresectable Solid Tumors
01/25
01/25
NCI10217, NCT03842228: Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

Active, not recruiting
1
108
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Copanlisib Hydrochloride, 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2), Aliqopa, BAY 80-6946 Dihydrochloride, BAY-80-6946 Dihydrochloride, Copanlisib Dihydrochloride, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
12/24
12/24
ACESOT-1051, NCT06260514: Study of APR-1051 in Patients With Advanced Solid Tumors

Recruiting
1
79
US
APR-1051
Aprea Therapeutics
Advanced Solid Tumor
06/27
06/28
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors

Hourglass Oct 2019 - Mar 2020 : From AMBER trial
Checkmark From AMBER trial at SITC 2018 [screenshot]
Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot]
Checkmark From AMBER trial in combination with TSR-022 at SITC 2018
Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018
Recruiting
1
447
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Tesaro, Inc.
Neoplasms
04/25
04/27
NCT04991480: A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Active, not recruiting
1
390
Europe, US
ART4215, Talazoparib, Talzenna, Niraparib, Zejula
Artios Pharma Ltd
Advanced Cancer, Metastatic Cancer, Breast Cancer
03/25
08/25
NCT04693468: Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

Recruiting
1
111
US
Axitinib, AG-013736, AG013736, Inlyta, Crizotinib, MET Tyrosine Kinase Inhibitor PF-02341066, PF-02341066, PF-2341066, Xalkori, Palbociclib Isethionate, PD 0332991-0054, PF-00080665-73, Talazoparib Tosylate, Talzenna
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
09/25
09/25
NCT05039801: IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Recruiting
1
54
US
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Zirabev, Glutaminase-1 Inhibitor IACS-6274, GLS1 Inhibitor IACS-6274, IACS 6274, IACS-6274, IACS6274, IPN 60090, IPN-60090, IPN60090, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Capivasertib, AZD5363
M.D. Anderson Cancer Center
Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Clear Cell Adenocarcinoma, Chondrosarcoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Recurrent Ovarian High Grade Serous Adenocarcinoma, Refractory Endometrial Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma, Refractory Melanoma, Refractory Ovarian Clear Cell Adenocarcinoma, Refractory Ovarian High Grade Serous Adenocarcinoma, Stage III Ovarian Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
05/26
05/26
NCT05838768: Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

Recruiting
1
327
Europe, Japan, US, RoW
HRO761, tislelizumab, VDT482, irinotecan
Novartis Pharmaceuticals
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
01/30
01/30
Petit, Robert
AOST-2121, NCT04974008: Osteosarcoma Maintenance Therapy With OST31-164

Completed
2
39
US
OST31-164
George Clinical Pty Ltd
Bone Cancer
09/23
09/23
ORB, NCT05947474: -011 In Patients With Advanced Solid Tumors

Recruiting
1
36
US
ORB-011
Orionis Biosciences Inc
Advanced Solid Cancer
03/25
06/25
Simeone, Diane
NCT04229004: A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

Active, not recruiting
3
825
US
Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88
Pancreatic Cancer Action Network
Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
06/27
06/27
FAPI-46 PDAC, NCT05262855: Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma

Recruiting
2
60
US
[68Ga]FAPI-46
SOFIE
PDAC - Pancreatic Ductal Adenocarcinoma, FAP
12/24
12/24
EVEREST-1, NCT05736731: A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

Recruiting
1/2
160
US
A2B530, Tmod CAR T-cell Therapy, xT-Onco with HLA-LOH Assay
A2 Biotherapeutics Inc., Tempus AI
Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent, Non-Small Cell Squamous Lung Cancer, NSCLC, NSCLC, Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, CRC, Colorectal Cancer Metastatic, Cancer
12/26
12/28
NCT03334708: A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma

Recruiting
N/A
700
US, RoW
Blood Draw, Tumor Tissue Collection, Cyst Fluid
Memorial Sloan Kettering Cancer Center, Sheba Medical Center, Weill Medical College of Cornell University, Weizmann Institute of Science
Pancreatic Cancer, Pancreatic Diseases, Pancreatitis, Pancreatic Cyst
10/24
10/24
BASECAMP-1, NCT04981119: Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Recruiting
N/A
200
US
Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing
A2 Biotherapeutics Inc., Tempus AI
Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, CRC, NSCLC, Pancreas Cancer, Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Mesothelioma, Malignant, Mesothelioma; Lung, Cancer
12/24
12/26
PRECEDE, NCT04970056: Pancreatic Cancer Early Detection Consortium

Recruiting
N/A
8000
Europe, Canada, US, RoW
Arbor Research Collaborative for Health
Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
12/30
12/30
EA2185, NCT04239573: Comparing Two Methods to Follow Patients With Pancreatic Cysts

Recruiting
N/A
4606
Canada, US, RoW
Computed Tomography, CAT, CAT scan, Computerized Axial Tomography, computerized tomography, CT, CT scan, tomography, Endoscopic Ultrasound, endosonography, EUS, Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, nuclear magnetic resonance imaging, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Pancreatic Carcinoma
07/33
07/33
McAllister, Florencia
NCT04975217: Fecal Microbial Transplants for the Treatment of Pancreatic Cancer

Recruiting
1
10
US
Fecal Microbiota Transplantation, Fecal Material Transplantation, Fecal Transplantation, FMT, Poo Transplant, Poop Transplant, Stool Transplant, Fecal Microbiota Transplantation Capsule, Fecal Microbiota Preparation Delivery Capsule, FMPCapDE, FMT Capsule DE, FMT Capsule Delivery, FMT DE Capsule, Questionnaire Administration, Resection, Surgical Resection, Therapeutic Colonoscopy
M.D. Anderson Cancer Center
Pancreatic Ductal Adenocarcinoma
12/26
12/26
NCT05873699: Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection

Recruiting
1
10
US
Hyperpolarized 13-C-pyruvate
M.D. Anderson Cancer Center
Pancreatic Cyst
01/25
01/26
PRECEDE, NCT04970056: Pancreatic Cancer Early Detection Consortium

Recruiting
N/A
8000
Europe, Canada, US, RoW
Arbor Research Collaborative for Health
Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
12/30
12/30
Baydogan, Seyda
PRECEDE, NCT04970056: Pancreatic Cancer Early Detection Consortium

Recruiting
N/A
8000
Europe, Canada, US, RoW
Arbor Research Collaborative for Health
Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
12/30
12/30
Bessmer, Chris
ELEVATE 2, NCT04712669 / 2020-004971-42: A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension

Completed
2
108
Europe, Canada, US, RoW
rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo
Altavant Sciences GmbH
Pulmonary Arterial Hypertension
06/23
08/23
PRECEDE, NCT04970056: Pancreatic Cancer Early Detection Consortium

Recruiting
N/A
8000
Europe, Canada, US, RoW
Arbor Research Collaborative for Health
Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
12/30
12/30
Hogg, Melissa
PRECEDE, NCT04970056: Pancreatic Cancer Early Detection Consortium

Recruiting
N/A
8000
Europe, Canada, US, RoW
Arbor Research Collaborative for Health
Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
12/30
12/30
EA2185, NCT04239573: Comparing Two Methods to Follow Patients With Pancreatic Cysts

Recruiting
N/A
4606
Canada, US, RoW
Computed Tomography, CAT, CAT scan, Computerized Axial Tomography, computerized tomography, CT, CT scan, tomography, Endoscopic Ultrasound, endosonography, EUS, Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, nuclear magnetic resonance imaging, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Pancreatic Carcinoma
07/33
07/33
Kanlikilicer, Pinar
PRECEDE, NCT04970056: Pancreatic Cancer Early Detection Consortium

Recruiting
N/A
8000
Europe, Canada, US, RoW
Arbor Research Collaborative for Health
Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
12/30
12/30
Radakovitz, Courtney
PRECEDE, NCT04970056: Pancreatic Cancer Early Detection Consortium

Recruiting
N/A
8000
Europe, Canada, US, RoW
Arbor Research Collaborative for Health
Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
12/30
12/30

Download Options